secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001193125-25-291443
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial
--------------------------------------------------------------------------------

- Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.
- Underwriters granted 30-day option to purchase up to 10.3M additional shares.
- Company amended Series A-1 and B-1 warrants to reflect plan to advance IKT-001 to global pivotal Phase 3 trial in PAH.
- Offering expected to close November 24, 2025; shelf registration effective June 27, 2025.
- Jefferies, BofA Securities, and Cantor Fitzgerald are representatives of the underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/0001193125-25-291443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525291443/d65626d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer